Point72 Hong Kong LTD Tricida, Inc. Transaction History

Point72 Hong Kong LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$4.37 - $9.46 $1,494 - $3,235	-342 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$8.56 - $26.93 $2,199 - $6,921	257 Added 302.35%	342 $3,000
Q2 2020 Aug 14, 2020	SELL	$21.21 - $31.55 $8,038 - $11,957	-379 Reduced 81.68%	85 $2,000
Q1 2020 May 15, 2020	BUY	$18.43 - $38.04 $7,574 - $15,634	411 Added 775.47%	464 $10,000
Q4 2019 Feb 14, 2020	BUY	$29.6 - $43.71 $1,568 - $2,316	53 New	53 $2,000
Q3 2019 Nov 14, 2019	SELL	$29.87 - $42.22 $597 - $844	-20 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$31.16 - $39.46 $623 - $789	20 New	20 $1,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.